Andrew Hopkins

Andrew Hopkins is the Founder and Chief Executive of Exscientia plc, a precision medicine company pioneering the use of artificial intelligence (AI) and machine learning (ML) to design new drug candidates.

He led the teams that discovered the first AI-designed drugs to enter human clinical trials. Under Andrew’s leadership, Exscientia listed on the NASDAQ in October 2021 and is recognised as the most successful UK university spin out company of the past decade. He leads a global team of around 450 scientists and technology experts based in the UK, Austria, US and beyond. For its end-to-end AI-driven precision medicine platform, Exscientia won the Prix Galien USA 2022 for Best Digital Health Solution and the Prix Galien UK 2023 in the same category.

Andrew holds an honorary Professorship at the University of Dundee, where he previously held the Chairs of Medicinal Informatics and Translational Biology. He served as the Director of the Scottish Universities Life Science Alliance and co-founded the European Lead Factory. Prior to the University of Dundee, he spent a decade at Pfizer leading various informatics groups. Andrew received his DPhil in biophysics from the University of Oxford and LLD from the University of Dundee.

In 2023, he was elected for life a Fellow of the Royal Society as well as a Fellow of the UK Academy of Medical Sciences in recognition of “exceptional contributions to science”. Also in 2023, Andrew featured on the inaugural TIME100 AI list of most influential people in AI. On December 30, 2023, he was appointed Commander of the Order of the British Empire (CBE) in the 2024 New Year Honours List by HM King Charles III, for services to Science and to Innovation.